Table of Contents

company-logo

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

Infant Bacterial Therapeutics Dividend Announcement

• Infant Bacterial Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Infant Bacterial Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Infant Bacterial Therapeutics Dividend History

Infant Bacterial Therapeutics Dividend Yield

Infant Bacterial Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Infant Bacterial Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Infant Bacterial Therapeutics Financial Ratios

P/E ratio-3.65
PEG ratio-0.07
P/B ratio2.58
ROE-56.31%
Payout ratio0.00%
Current ratio6.52
Quick ratio6.52
Cash Ratio6.41

Infant Bacterial Therapeutics Dividend FAQ

Does Infant Bacterial Therapeutics stock pay dividends?
Infant Bacterial Therapeutics does not currently pay dividends to its shareholders.
Has Infant Bacterial Therapeutics ever paid a dividend?
No, Infant Bacterial Therapeutics has no a history of paying dividends to its shareholders. Infant Bacterial Therapeutics is not known for its dividend payments.
Why doesn't Infant Bacterial Therapeutics pay dividends?
There are several potential reasons why Infant Bacterial Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Infant Bacterial Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Infant Bacterial Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Infant Bacterial Therapeutics a dividend aristocrat?
Infant Bacterial Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Infant Bacterial Therapeutics a dividend king?
Infant Bacterial Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Infant Bacterial Therapeutics a dividend stock?
No, Infant Bacterial Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Infant Bacterial Therapeutics stocks?
To buy Infant Bacterial Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Infant Bacterial Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.